<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1996-3521</journal-id>
<journal-title><![CDATA[Infodir]]></journal-title>
<abbrev-journal-title><![CDATA[Infodir]]></abbrev-journal-title>
<issn>1996-3521</issn>
<publisher>
<publisher-name><![CDATA[Editorial de Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1996-35212023000100005</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Eficiencia e impacto presupuestario del nimotuzumab en el cáncer de cabeza y cuello]]></article-title>
<article-title xml:lang="en"><![CDATA[Efficiency and budget impact of nimotuzumab in head and neck cancer]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Ruiz]]></surname>
<given-names><![CDATA[Leslie]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Collazo Herrera]]></surname>
<given-names><![CDATA[Manuel Miguel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Iznaga Escobar]]></surname>
<given-names><![CDATA[Normando Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro de Inmunología Molecular (CIM)  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Higiene, Epidemiología y Microbiología (INHEM)  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2023</year>
</pub-date>
<numero>40</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1996-35212023000100005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1996-35212023000100005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1996-35212023000100005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  Desde la perspectiva de la economía de la salud, no existen evidencias de la eficiencia del nimotuzumab en el tratamiento con los pacientes diagnosticados con cáncer de células escamosas de cabeza y cuello en estadios avanzados.  Objetivos:  Evaluar eficiencia de la incorporación del nimotuzumab al sistema de salud cubano como tratamiento en el cáncer de cabeza y cuello.  Métodos:  Se realizaron dos evaluaciones económicas costo-efectividad, basadas en los ensayos clínicos fases III y IV, y un análisis de impacto presupuestal. El universo estuvo integrado por todos los pacientes incluidos en ambos estudios. Se calcularon el costo/efectividad medio, la razón coste-efectividad incremental y el impacto presupuestal. La información se obtuvo de los cuadernos de recogida de datos de los ensayos y se siguió la metodología establecida para la realización de evaluaciones económicas.  Resultados:  La primera evaluación arrojó que la combinación nimotuzumab-radioterapia fue una opción eficiente. En la segunda evaluación, la alternativa radioterapia/quimioterapia secuencial más nimotuzumab resultó no costo-efectiva, aunque al estar el fármaco incluido en el esquema terapéutico del Ministerio de Salud Pública, se considera un umbral para tratamientos oncológicos de $33 000/años de vida ganados. El análisis de impacto presupuestario arrojó, que aplicar pautas de administración del nimotuzumab más cortas, lograría un costo evitado entre 8-50 millones de pesos cubanos.  Conclusiones:  La incorporación del nimotuzumab significa un costo adicional al sistema de salud, pero su efectividad y seguridad, ameritan su empleo y confección de nuevas guías de tratamiento basadas en evidencia de su eficiencia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  From a health economics perspective, there is no evidence of the efficiency of nimotuzumab in the treatment of patients diagnosed with advanced stages of head and neck squamous cell cancer.  Objectives:  To evaluate the efficiency of incorporating nimotuzumab into the Cuban health system as a treatment for head and neck cancer.  Methods:  Two economic cost-effectiveness evaluations were carried out, based on phase III and IV clinical trials, and a budget impact analysis. The universe consisted of all patients included in both studies. Mean cost-effectiveness, incremental cost-effectiveness ratio and budget impact were calculated. Information was obtained from the data collection booklets of the trials and the established methodology for conducting economic evaluations was followed.  Results:  The first evaluation showed that the nimotuzumab-radiotherapy combination was an efficient option. In the second evaluation, the sequential radiotherapy/chemotherapy plus nimotuzumab alternative was not cost-effective, although as the drug is included in the Ministry of Public Health's therapeutic scheme, a threshold for cancer treatment of $33,000/life-years gained is considered. The budget impact analysis showed that applying shorter nimotuzumab administration schedules would achieve an avoided cost of between 8-50 million Cuban pesos.  Conclusions:  The incorporation of nimotuzumab means an additional cost to the health system, but its effectiveness and safety merit its use and the development of new treatment guidelines based on evidence of its efficacy.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[evaluación económica]]></kwd>
<kwd lng="es"><![CDATA[farmacoeconomía]]></kwd>
<kwd lng="es"><![CDATA[impacto presupuestal]]></kwd>
<kwd lng="es"><![CDATA[nimotuzumab]]></kwd>
<kwd lng="es"><![CDATA[carcinoma de células escamosas de cabeza y cuello]]></kwd>
<kwd lng="en"><![CDATA[economic evaluation]]></kwd>
<kwd lng="en"><![CDATA[pharmacoeconomics]]></kwd>
<kwd lng="en"><![CDATA[budgetary impact]]></kwd>
<kwd lng="en"><![CDATA[nimotuzumab]]></kwd>
<kwd lng="en"><![CDATA[head and neck squamous cell carcinoma]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Anuario Estadístico de Cuba 2021]]></source>
<year>2022</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[MINSAP: Dirección Nacional de Registros Médicos y Estadísticas de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pester]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Spencer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Adelstein]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Adkins]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Anzai]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Brizel]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers, Version 2.2020]]></article-title>
<source><![CDATA[J Natl Compr Canc Netw]]></source>
<year>2020</year>
<volume>18</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>873-98</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Gonçalves]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Silvério]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Henrique]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A prospective study on oral adverse effects in head and neck cancer patients submitted to a preventive oral care protocol]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2020</year>
<volume>28</volume>
<page-range>4263-73</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreiro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Barceló]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rubio]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quimioterapia: efectos secundarios]]></article-title>
<source><![CDATA[Gac Med Bilbao]]></source>
<year>2003</year>
<volume>100</volume>
<page-range>69-74</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<collab>Centro Estatal para el Control de Medicamentos (CECMED)</collab>
<source><![CDATA[Nimotuzumab. Resumen de las características del producto]]></source>
<year>2020</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[CECMED]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<collab>ACTION Study Group.Jan S.Kimman M.Peters SA.Woodward M</collab>
<article-title xml:lang=""><![CDATA[Financial catastrophe, treatment discontinuation and death associated with surgically operable cancer in South-East Asia Results from the ACTION Study]]></article-title>
<source><![CDATA[Surgery]]></source>
<year>2015</year>
<volume>157</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>971-82</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patterson]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Fischman]]></surname>
<given-names><![CDATA[VG]]></given-names>
</name>
<name>
<surname><![CDATA[Wasserman]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Siu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shrime]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Fagan]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global burden of head and neck cancer economic consequences, health, and the role of surgery]]></article-title>
<source><![CDATA[Otolaryngol Head Neck Surg]]></source>
<year>2020</year>
<volume>162</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>296-303</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prasad]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Afifi]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Mailankody]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The rising price of cancer drugs-a new old problem]]></article-title>
<source><![CDATA[JAMA Oncol]]></source>
<year>2017</year>
<volume>3</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>277-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Collazo]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Iznaga]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Viada]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación económica del tratamiento con nimotuzumab para el cáncer de cabeza y cuello en Cuba]]></article-title>
<source><![CDATA[PharmacoEcon Span Res Artic]]></source>
<year>2016</year>
<volume>13</volume>
<page-range>133-40</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mauskopf]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Earnshaw]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Brogan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wolowacz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Brodtkorb]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
</person-group>
<source><![CDATA[Budget-Impact Analysis of Health Care Interventions. A practical guide]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Switzerland ]]></publisher-loc>
<publisher-name><![CDATA[Springer International Publishing AG]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Evaluación económica de medicamentos y tecnologías sanitarias. Cap. 1, Fundamento e introducción a la evaluación económica de medicamentos y tecnologías sanitarias]]></source>
<year>2012</year>
<page-range>9-20</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Springer SBM Spain, S.A.U]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>ICH Expert Working Group</collab>
<source><![CDATA[ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials E9 version 4]]></source>
<year>1998</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[ICH Expert Working Group]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marrero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bases conceptuales y metodológicas para estimar el costo de las enfermedades neumocócicas en niños en el primer nivel de atención de salud]]></article-title>
<source><![CDATA[Rev. Cubana de Salud Pública]]></source>
<year>2017</year>
<volume>43</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>610-20</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marseille]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Larson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kazi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kahn]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Rosen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thresholds for the cost-effectiveness of interventions alternative approaches]]></article-title>
<source><![CDATA[Bull World Health Organ]]></source>
<year>2015</year>
<volume>93</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>118-24</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<collab>Oficina Nacional de Estadística e Información (ONEI)</collab>
<source><![CDATA[Anuario Estadístico Cuba 2020. Cap. 5. Cuentas nacionales]]></source>
<year>2021</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[ONEI]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Briggs]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Claxton]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sculpher]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Decision Modelling for Health Economic Evaluation]]></source>
<year>2011</year>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Oxford University Press Inc]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<collab>Consejo de Salubridad General</collab>
<source><![CDATA[Guía para la Conducción de Estudios de Evaluación Económica para la Actualización del Cuadro Básico y Catálogo de Insumos del Sector Salud en México]]></source>
<year>2017</year>
<publisher-loc><![CDATA[México DF ]]></publisher-loc>
<publisher-name><![CDATA[Dirección General Adjunta de Priorización]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Mauskopf]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Augustovski]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Caro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Minchin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Budget Impact Analysis-Principles of Good Practice Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force]]></article-title>
<source><![CDATA[Value in health;]]></source>
<year>2014</year>
<volume>17</volume>
<page-range>5-14</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alfonso]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Broche]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Calvo]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Formulario Nacional de Medicamentos]]></source>
<year>2014</year>
<edition>4</edition>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[ECIMED]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patil]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
<name>
<surname><![CDATA[Noronha]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Agarwal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ghosh-Laskar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Budrukkar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2019</year>
<volume>125</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>3184-97</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maasland]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alcohol consumption, cigarette smoking and the risk of subtypes of head-neck cancer results from the Netherlands Cohort Study]]></article-title>
<collab>van den Brandt PA.Kremer B.Goldbohm RA.Schouten LJ</collab>
<source><![CDATA[BMC Cancer]]></source>
<year>2014</year>
<volume>14</volume>
<page-range>187</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardemil]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiología del carcinoma escamoso de cabeza y cuello Rev Chil Cir]]></article-title>
<source><![CDATA[Dic]]></source>
<year>2014</year>
<volume>6</volume>
<numero>66</numero>
<issue>66</issue>
<page-range>614-20</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crombet]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mestre]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mazorra]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Iznaga]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nimotuzumab for patients with inoperable cancer of head and neck]]></article-title>
<source><![CDATA[Front. Oncol]]></source>
<year>2020</year>
<volume>10</volume>
<numero>817</numero>
<issue>817</issue>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Viada]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Vega]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Robaina]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Frías]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Santiesteban]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación de Nimotuzumab para el tratamiento de cáncer de cabeza y cuello: Meta-análisis de ensayos controlados]]></article-title>
<source><![CDATA[BioNatura]]></source>
<year>2020</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1056-62</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vega]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vila]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Venereo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Valls]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[De Armas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and effectiveness of nimotuzumab in the treatment of advanced head and neck cancer patients Phase IV clinical trial: final results]]></article-title>
<source><![CDATA[JJ Cancer Sci Res]]></source>
<year>2019</year>
<volume>4</volume>
<page-range>057</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ang]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenthal]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen-Tan]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Sherman]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma RTOG 0522]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2014</year>
<volume>32</volume>
<page-range>2940-50</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mesía]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Henke]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fortin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Minn]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yunes Ancona]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Cmelak]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1) a randomised, controlled, open-label phase 2 trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2015</year>
<volume>16</volume>
<page-range>208-20</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[León]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Hitt]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Constenla]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rocca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Stupp]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kovács]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A retrospective analysis of the outcome of patients with recurrent or metastatic squamous cell carcinoma of the head and neck who are progressing while on a platinum-based palliative chemotherapy]]></article-title>
<source><![CDATA[Proc Am Soc Clin Oncol]]></source>
<year>2003</year>
<volume>22</volume>
<page-range>502</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herbst]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Arquette]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shin]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Dicke]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Vokes]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Azarnia]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2005</year>
<volume>23</volume>
<page-range>5578-87</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baselga]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Trigo]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Bourhis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tortochaux]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cortes-Funes]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hitt]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A phase II multicenter study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2005</year>
<volume>23</volume>
<page-range>5568-77</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trigo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hitt]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Koralewski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz-Rubio]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rolland]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Knecht]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) results of a phase II study]]></article-title>
<source><![CDATA[Proc Am Soc Clin Oncol]]></source>
<year>2004</year>
<volume>23</volume>
<page-range>487</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vermorken]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Mesia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Platinum-based chemotherapy plus cetuximab in head and neck cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2008</year>
<volume>359</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1116-27</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burtness]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Goldwasser]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Flood]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Mattar]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Forastiere]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eastern Cooperative Oncology Group Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2005</year>
<volume>23</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>8646-54</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cressman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Browman]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Hoch]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Kovacic]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Peacock]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A time-trend economic analysis of cancer drug trials]]></article-title>
<source><![CDATA[The Oncologist]]></source>
<year>2015</year>
<volume>20</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bagust]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Greenhalgh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Boland]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fleeman]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[McLeod]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Dickson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck A NICE Single Technology Appraisal]]></article-title>
<source><![CDATA[Pharmacoeconomics]]></source>
<year>2010</year>
<volume>28</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>439-48</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Longson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Update report on the application of the "end-of-life" supplementary advice in health technology appraisals]]></source>
<year>2009</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Centre for Health Technology Evaluation Peter Littlejohns]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walton]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process]]></article-title>
<collab>O'Connor J.Carroll C.Claxton L.Hodgson R</collab>
<source><![CDATA[Pharmacoecon Open]]></source>
<year>2019</year>
<volume>3</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>403-10</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hannouf]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Sehgal]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[JQ]]></given-names>
</name>
<name>
<surname><![CDATA[Mocanu]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Winquist]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Zari]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First Line Treatment of Recurrent or Metastatic Head and Neck Cancer]]></article-title>
<source><![CDATA[PLoS ONE]]></source>
<year>2012</year>
<volume>7</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Dong]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cetuximab Plus Chemotherapy versus Chemotherapy Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma A Cost-Effectiveness Analysis]]></article-title>
<source><![CDATA[Cancer Management and Research]]></source>
<year>2020</year>
<volume>12</volume>
<page-range>11383-90</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Frómeta]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mestre]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Diagnóstico y Tratamiento del Cáncer de Cabeza y Cuello]]></source>
<year>2019</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Editorial de Ciencias Médicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Puig]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Oliva]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Trapero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Abellán]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Brosa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Guía y recomendaciones para la realización y presentación de evaluaciones económicas y análisis de impacto presupuestario de medicamentos en el ámbito del CatSalut]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Departament de Salut. Servei Català de la Salut]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
